Tenaya Therapeutics, Inc. Other Comprehensive Income (Loss), Net of Tax
Tenaya Therapeutics, Inc. (TNYA) reported Other Comprehensive Income (Loss), Net of Tax of -$28.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-05
- Tenaya Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was $1.00K, a 99.30% decline year-over-year.
- Tenaya Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-06-30 was $9.00K, a 83.02% decline year-over-year.
- Tenaya Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-03-31 was -$38.00K.
- Tenaya Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2024-09-30 was $143.00K, a 98.61% increase year-over-year.
- Tenaya Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2025 was -$28.00K, a 120.90% decline from fiscal 2024.
- Tenaya Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2024 was $134.00K, a 50.74% decline from fiscal 2023.
- Tenaya Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2023 was $272.00K.
- Tenaya Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2022 was -$237.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$28.00K 10-K · filed 2026-03-11 | |||
| 2025-09-30 | $1.00K 10-Q · filed 2025-11-10 | $10.00K derived: sum of 2 quarters · filed 2026-08-05 | -$28.00K derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | $9.00K 10-Q · filed 2026-08-05 | -$29.00K derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | -$38.00K 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $134.00K 10-K · filed 2026-03-11 | |||
| 2024-09-30 | $143.00K 10-Q · filed 2025-11-10 | $196.00K derived: sum of 2 quarters · filed 2025-11-10 | $182.00K derived: sum of 3 quarters · filed 2025-11-10 | |
| 2024-06-30 | $53.00K 10-Q · filed 2025-11-10 | $39.00K derived: sum of 2 quarters · filed 2025-11-10 | ||
| 2024-03-31 | -$14.00K 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | $272.00K 10-K · filed 2025-03-10 | |||
| 2023-09-30 | $72.00K 10-Q · filed 2024-11-06 | -$141.00K derived: sum of 2 quarters · filed 2024-11-06 | $117.00K derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | -$213.00K 10-Q · filed 2024-11-06 | $45.00K derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $258.00K 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | -$237.00K 10-K · filed 2024-03-18 | |||
| 2022-09-30 | -$28.00K 10-Q · filed 2023-11-08 | -$136.00K derived: sum of 2 quarters · filed 2023-11-08 | -$626.00K derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-30 | -$108.00K 10-Q · filed 2023-11-08 | -$598.00K derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-31 | -$490.00K 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | -$141.00K 10-K · filed 2023-03-08 | |||
| 2021-09-30 | -$23.00K 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |